A Dose-Escalation Study Demonstrates the Safety and Tolerability of Cellobiose in Healthy Subjects

Documenti analoghi

• First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects
  di: Banfield, Christopher, et al.
  Pubblicazione: (2020)
• Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects
  di: Dvorchik, Barry H., et al.
  Pubblicazione: (2003)
• Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects
  di: Uebelhack, Ralf, et al.
  Pubblicazione: (2019)
• Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects
  di: Ralf Uebelhack, et al.
  Pubblicazione: (2019-01-01)
• Erratum to “Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects”
  di: Uebelhack, Ralf, et al.
  Pubblicazione: (2019)